+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Neurotrophic Keratitis Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • PDF Icon


  • 175 Pages
  • February 2024
  • Region: Global
  • Infogence Global Research
  • ID: 5650830

In 2022, The FDA approved Italian firm Dompé’s eye drop Oxervate for the treatment of neurotrophic keratitis

The Global Neurotrophic Keratitis Market is estimated to be USD 237.23 Mn in 2023 and is expected to reach USD 545.72 Mn by 2028 growing at a CAGR of 18.13%.

  • Neurotrophic keratitis is a rare degenerative eye problem marked by reduced corneal sensitivity caused by nerve injury. It causes reduced tear production, corneal ulcers, and possible vision loss. The illness is difficult to treat and requires careful control to prevent the corneal damage from increasing.
  • The rising prevalence of fungal keratitis, a serious fungi-caused eye illness, contributes to the rise in neurotrophic keratitis. Fungal keratitis can cause corneal damage, impairing nerve function and resulting in neurotrophic keratitis, a difficult condition to treat. The increase in visual impairment caused by fungal keratitis highlights the need for improved medicines and increasing knowledge of preventive measures.
  • Milder climates give ideal circumstances for fungal development, resulting in a higher incidence of fungal keratitis. As the infection worsens, it might compromise corneal sensitivity, leading to neurotrophic keratitis. The geographical association emphasizes the significance of developing specialized strategies and resources for these regions in order to treat the related neurotrophic keratitis burden.
  • The rising number of contact lens wearers and poor lens care raise the risk of infections such as fungal keratitis. Because of corneal nerve injury, these infections can eventually progress to neurotrophic keratitis. Improving public education on contact lens care is critical to reducing this avoidable cause of neurotrophic keratitis.
  • With the increasing prevalence of fungal keratitis as a cause of neurotrophic keratitis, there is a potential to develop and sell enhanced topical antifungal medicines. Antifungal, aggressive and successful drugs can help battle fungal infections more effectively, lowering the risk of neurotrophic keratitis and improving patient outcomes. Such inventions can address unmet market demands and provide improved therapeutic alternatives.
  • As our comprehension of fungal keratitis grows, there is a window of opportunity to engage in research and development of novel therapeutic options. Innovative therapeutics, such as targeted drug delivery systems, combination therapy, and new classes of antifungal drugs, have the potential to transform the treatment landscape for fungal keratitis and, as a result, reduce the incidence of neurotrophic keratitis. Market entrants with innovative products have the ability to make a substantial impact and achieve a competitive advantage.
  • However, in instances of fungal keratitis, the market is hindered by a lack of accurate antifungal recommendations suited to individual fungal isolations. The lack of personalized treatment guidelines hinders optimized therapy approaches, potentially leading to inferior outcomes and challenging, effective management of the condition.
  • The industry is being challenged by an increase in unsuccessful medical operations and fungal recurrence in patients with fungal keratitis. Recurrent infections can cause neurotrophic keratitis, encouraging new and more effective treatment options.

Market Segmentations

  • The Global Neurotrophic Keratitis Market is segmented based on Route of Administration, Distribution Channel, and Geography.
  • By Route of Administration, the Global Neurotrophic Keratitis Market is classified into Injection, Oral, Topical.
  • Topical holds a larger market share. It is favored because of its simplicity, lack of invasiveness, and direct application to the affected area. Topical drugs enable targeted therapy, making them a popular and easily accessible treatment choice for patients.
  • By Distribution Channel, the Global Neurotrophic Keratitis Market is classified into Drug Stores and Hospitals.
  • Hospitals hold a larger market share. Due to the condition's complexity and the necessity for specialized medical treatment and prescription medications, hospital distribution channels predominate. Cases of neurotrophic keratitis are often managed and treated in hospital settings by healthcare personnel.
  • By Geography, the Global Neurotrophic Keratitis Market is classified into the Americas, Europe, Middle-East & Africa, and Asia-Pacific.
  • The Americas hold a larger market share. This is due to factors such as higher healthcare spending, improved medical infrastructure, and increased knowledge of the disease, which has resulted in better diagnosis and treatment rates in the region when compared to others.

Recent Development

  • Alcon and Aerie Pharmaceuticals Inc. have announced the companies have entered into a definitive merger agreement through which Alcon will acquire Aerie. - August 2022
  • Kala Pharmaceuticals Inc. announced that it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was first announced in May. - July 2022

Company Profiles

The report provides a detailed analysis of the competitors in the market. It covers the financial performance analysis for the publicly listed companies in the market. The report also offers detailed information on the companies' recent development and competitive scenario. Some of the companies covered in this report are Alvogen, Bausch Health, Gilead Biosciences, Merck, etc.

Countries Studied

  • America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)
  • Europe (Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Luxemburg, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)
  • Middle-East and Africa (Egypt, Israel, Qatar, Nigeria, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)
  • Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

  • The report presents a detailed Ansoff matrix analysis for the Global Neurotrophic Keratitis Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development, and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.
  • The publisher analyses the Global Neurotrophic Keratitis Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • Based on the SWOT analysis conducted on the industry and industry players, the publisher has devised suitable strategies for market growth.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Neurotrophic Keratitis Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The research report also provides a detailed market size analysis and projections in volume and value terms. The projections are calculated using verified research methodologies.
  • Excel data sheet for the market size will also be provided with the report.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model, PESTLE Analysis, and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.
  • The report includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report includes Self-Assessment Form, which helps customers evaluate their position in the market compared to their competitors
  • The report offers customized research - tailored uniquely to our customers with a quick turnaround time. We offer a 15% customization option at no extra charge to all our clients for any of our syndicated reports.

Report Highlights:

  • A complete analysis of the market, including the parent industry
  • Important market dynamics and trends
  • Impact Analysis - a comprehensive assessment to confront risk and make strategic & operational decisions to counter the changes in the market environment.
  • Market segmentation
  • Competitive Analysis: Comparative analysis of competitor
  • Historical, current, and projected size of the market based on value and volume
  • Market size of the US states
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research0
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size, Segmentations, and Outlook
4 Market Dynamics
4.1 Impact Analysis
4.2 Drivers
4.2.1 Rising Visual Impairment Due to Fungal Keratitis
4.2.2 Increasing Number of Fungal Keratitis in Regions with Mild Temperature Climates
4.3 Restraints
4.3.1 Non-Availability of Antifungal Recommendations with Specific Fungal Isolation
4.4 Opportunities
4.4.1 Aggressive Topical Antifungal Therapy for the Treatment
4.4.2 New Product Developments in the Treatments of Fungal Keratitis
4.5 Challenges
4.5.1 Rising Number of Failed Medical Surgeries in a Reappearance of Fungus
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 PESTLE Analysis
5.4 Impact of COVID-19
5.5 Ansoff Matrix Analysis
6 Global Neurotrophic Keratitis Market, By Route of Administration
6.1 Introduction
6.2 Injection
6.3 Oral
6.4 Topical
7 Global Neurotrophic Keratitis Market, By Distribution Channel
7.1 Introduction
7.2 Drug Stores
7.3 Hospitals
8 America’s Neurotrophic Keratitis Market
8.1 Introduction
8.2 Argentina
8.3 Brazil
8.4 Canada
8.5 Chile
8.6 Colombia
8.7 Mexico
8.8 Peru
8.9 United States
8.10 Rest of Americas
9 Europe's Neurotrophic Keratitis Market
9.1 Introduction
9.2 Austria
9.3 Belgium
9.4 Denmark
9.5 Finland
9.6 France
9.7 Germany
9.8 Ireland
9.9 Italy
9.10 Luxembourg
9.11 Netherlands
9.12 Norway
9.13 Poland
9.14 Russia
9.15 Spain
9.16 Sweden
9.17 Switzerland
9.18 United Kingdom
9.19 Rest of Europe
10 Middle East and Africa's Neurotrophic Keratitis Market
10.1 Introduction
10.2 Egypt
10.3 Israel
10.4 Qatar
10.5 Nigeria
10.6 Saudi Arabia
10.7 South Africa
10.8 United Arab Emirates
10.9 Rest of MEA
11 APAC's Neurotrophic Keratitis Market
11.1 Introduction
11.2 Australia
11.3 Bangladesh
11.4 China
11.5 India
11.6 Indonesia
11.7 Japan
11.8 Malaysia
11.9 Philippines
11.10 Singapore
11.11 South Korea
11.12 Sri Lanka
11.13 Thailand
11.14 Taiwan
11.15 Rest of Asia-Pacific
12 Competitive Landscape
12.1 Competitive Quadrant
12.2 Market Share Analysis
13 Company Profiles
13.1 AbbVie Inc.
13.1.1 Company Overview
13.1.2 Company Snapshot
13.1.3 Product Overview
13.1.4 Business Overview
13.1.5 SWOT Analysis
13.1.6 Recent Developments
13.2 Alcon
13.2.1 Company Overview
13.2.2 Company Snapshot
13.2.3 Product Overview
13.2.4 Business Overview
13.2.5 SWOT Analysis
13.2.6 Recent Developments
13.3 Alvogen
13.3.1 Company Overview
13.3.2 Company Snapshot
13.3.3 Product Overview
13.3.4 Business Overview
13.3.5 SWOT Analysis
13.3.6 Recent Developments
13.4 Auroa Pharmaceutical Inc.
13.4.1 Company Overview
13.4.2 Company Snapshot
13.4.3 Product Overview
13.4.4 Business Overview
13.4.5 SWOT Analysis
13.4.6 Recent Developments
13.5 Bausch Health
13.5.1 Company Overview
13.5.2 Company Snapshot
13.5.3 Product Overview
13.5.4 Business Overview
13.5.5 SWOT Analysis
13.5.6 Recent Developments
13.6 BridgeBio Pharma, Inc.
13.6.1 Company Overview
13.6.2 Company Snapshot
13.6.3 Product Overview
13.6.4 Business Overview
13.6.5 SWOT Analysis
13.6.6 Recent Developments
13.7 Bristol Myers Squibb Company
13.7.1 Company Overview
13.7.2 Company Snapshot
13.7.3 Product Overview
13.7.4 Business Overview
13.7.5 SWOT Analysis
13.7.6 Recent Developments
13.8 Eyevance
13.8.1 Company Overview
13.8.2 Company Snapshot
13.8.3 Product Overview
13.8.4 Business Overview
13.8.5 SWOT Analysis
13.8.6 Recent Developments
13.9 Gilead Biosciences
13.9.1 Company Overview
13.9.2 Company Snapshot
13.9.3 Product Overview
13.9.4 Business Overview
13.9.5 SWOT Analysis
13.9.6 Recent Developments
13.10 Glenmark
13.10.1 Company Overview
13.10.2 Company Snapshot
13.10.3 Product Overview
13.10.4 Business Overview
13.10.5 SWOT Analysis
13.10.6 Recent Developments
13.11 Johnson & Johnson
13.11.1 Company Overview
13.11.2 Company Snapshot
13.11.3 Product Overview
13.11.4 Business Overview
13.11.5 SWOT Analysis
13.11.6 Recent Developments
13.12 Kala Pharmaceuticals, Inc.
13.12.1 Company Overview
13.12.2 Company Snapshot
13.12.3 Product Overview
13.12.4 Business Overview
13.12.5 SWOT Analysis
13.12.6 Recent Developments
13.13 Leadiant Biosciences
13.13.1 Company Overview
13.13.2 Company Snapshot
13.13.3 Product Overview
13.13.4 Business Overview
13.13.5 SWOT Analysis
13.13.6 Recent Developments
13.14 Merck
13.14.1 Company Overview
13.14.2 Company Snapshot
13.14.3 Product Overview
13.14.4 Business Overview
13.14.5 SWOT Analysis
13.14.6 Recent Developments
13.15 Novartis AG
13.15.1 Company Overview
13.15.2 Company Snapshot
13.15.3 Product Overview
13.15.4 Business Overview
13.15.5 SWOT Analysis
13.15.6 Recent Developments
13.16 Novo Holdings
13.16.1 Company Overview
13.16.2 Company Snapshot
13.16.3 Product Overview
13.16.4 Business Overview
13.16.5 SWOT Analysis
13.16.6 Recent Developments
13.17 Otsuka Pharmaceutical Co., Ltd.
13.17.1 Company Overview
13.17.2 Company Snapshot
13.17.3 Product Overview
13.17.4 Business Overview
13.17.5 SWOT Analysis
13.17.6 Recent Developments
13.18 Pfizer
13.18.1 Company Overview
13.18.2 Company Snapshot
13.18.3 Product Overview
13.18.4 Business Overview
13.18.5 SWOT Analysis
13.18.6 Recent Developments
13.19 Santen Pharmaceuticals
13.19.1 Company Overview
13.19.2 Company Snapshot
13.19.3 Product Overview
13.19.4 Business Overview
13.19.5 SWOT Analysis
13.19.6 Recent Developments
13.20 Sun Pharmaceutical Industries Ltd.
13.20.1 Company Overview
13.20.2 Company Snapshot
13.20.3 Product Overview
13.20.4 Business Overview
13.20.5 SWOT Analysis
13.20.6 Recent Developments
14 Appendix
14.1 Self-Assessment Form

Companies Mentioned

  • AbbVie Inc.
  • Alcon
  • Alvogen
  • Auroa Pharmaceutical Inc.
  • Bausch Health
  • BridgeBio Pharma, Inc.
  • Bristol Myers Squibb Company
  • Eyevance
  • Gilead Biosciences
  • Glenmark
  • Johnson & Johnson
  • Kala Pharmaceuticals, Inc.
  • Leadiant Biosciences
  • Merck
  • Novartis AG
  • Novo Holdings
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer
  • Santen Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.

Table Information